Jojima, T., Tomotsune, T., Iijima, T., Akimoto, K., Suzuki, K., & Aso, Y. (2016). Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes. Diabetol Metab Syndr.

Jojima, Teruo, Takanori Tomotsune, Toshie Iijima, Kazumi Akimoto, Kunihiro Suzuki, i Yoshimasa Aso. "Empagliflozin (an SGLT2 Inhibitor), Alone or in Combination With Linagliptin (a DPP-4 Inhibitor), Prevents Steatohepatitis in a Novel Mouse Model of Non-alcoholic Steatohepatitis and Diabetes." Diabetol Metab Syndr 2016.

Jojima, Teruo, et al. "Empagliflozin (an SGLT2 Inhibitor), Alone or in Combination With Linagliptin (a DPP-4 Inhibitor), Prevents Steatohepatitis in a Novel Mouse Model of Non-alcoholic Steatohepatitis and Diabetes." Diabetol Metab Syndr 2016.